Physician profile
Robert M Ricketts
NPI 1982834198
$796.16
in general payments reported to CMS, 2019-2025
10 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2022: $111 · 2023: $21.20 · 2024: $255 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.84 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $225.84 | 2019-2025 | |
| Lilly USA, LLC | $100.65 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $66.65 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $49.10 | 2024-2025 | Repatha, Otezla, Otezla |
| Biosense Webster, INC. | $21.20 | 2023 | Carto 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.19 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.55 | 2025 | Jardiance |
| Astellas Pharma US INC | $15.35 | 2024 | Veozah |
| Abbvie INC. | $13.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ricketts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.